文献速递姑息放疗与转移瘤

部分消融体部放疗(PABR):局部晚期巨大不可切除软组织肉瘤姑息放疗的新方法

Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas.
PubMed 文献 · Radiother Oncol · 2024-02-25

回顾性分析18例组织学证实肉瘤患者,2020年1月至2023年10月接受部分消融体部放疗(PABR),肿瘤核心给予高消融剂量、周边给予低姑息剂量。中位随访11个月,88.9%患者达部分缓解,平均绝对肿瘤体积缩小49.5%,所有有症状患者症状改善,无3级及以上毒性。

要点

  • PABR对巨大不可切除肉瘤似安全,可能提供良好症状缓解、肿瘤减容和局部控制。
  • 18例中88.9%达部分缓解,平均绝对肿瘤体积缩小49.5%,所有有症状患者症状改善。
  • 中位随访11个月,1年总生存率61%、无局部进展生存率83.3%、无远处进展生存率34.8%,无3级及以上毒性。

核心结论

  • PABR对巨大不可切除肉瘤似安全,可能提供良好症状缓解、肿瘤减容和局部控制,进一步研究正在进行中。

研究设计与样本

  • 回顾性分析2020年1月至2023年10月接受PABR的18例组织学证实肉瘤患者。
  • 原发终点为症状缓解率和结构缓解率,继发终点为总生存、无局部进展生存、无远处进展生存及急性和晚期毒性率。

主要发现

  • 所有患者肿瘤≥5 cm,中位肿瘤体积985 cc,最常见症状为疼痛;中位年龄72.5岁,44.5%为ECOG 2-3。
  • 最常用方案为20 Gy分5次联合瘤内追加剂量50 Gy(83.3%)。
  • 中位随访11个月后,88.9%患者达部分缓解,平均绝对肿瘤体积缩小49.5%;所有有症状患者症状改善。
  • 1年总生存率61%、无局部进展生存率83.3%、无远处进展生存率34.8%;无3级及以上毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Locally advanced, bulky, unresectable sarcomas cause significant tumour mass effects, leading to burdensome symptoms. We have developed a novel Partially Ablative Body Radiotherapy (PABR) technique that delivers a high, ablative dose to the tumour core and a low, palliative dose to its periphery aiming to increase overall tumour response without significantly increasing treatment toxicity. AIM: This study aims to report the safety and oncologic outcomes of PABR in patients with bulky, unresectable sarcomas. METHODS AND MATERIALS: A total of 18 patients with histologically proven sarcoma treated with PABR from January 2020 to October 2023 were retrospectively reviewed. The primary endpoints were symptomatic and structural response rates. Secondary endpoints were overall survival, freedom from local progression, freedom from distant progression, and acute and late toxicity rates. RESULTS: All patients had tumours ≥5 cm with a median tumour volume of 985 cc, and the most common symptom was pain. The median age is 72.5 years and 44.5 % were ECOG 2-3. The most common regimen used was 20 Gy in 5 fractions with an intratumoral boost dose of 50 Gy (83.3 %). After a median follow-up of 11 months, 88.9 % of patients exhibited a partial response with a mean absolute tumour volume reduction of 49.5 %. All symptomatic patients experienced symptom improvement. One-year OS, FFLP and FFDP were 61 %, 83.3 % and 34.8 %, respectively. There were no grade 3 or higher toxicities. CONCLUSION: PABR for bulky, unresectable sarcomas appears to be safe and may provide good symptomatic response, tumour debulking, and local control. Further study is underway.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yu KK, Yeo A, Ngan S, et al. Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas. Radiother Oncol. 2024. PMID: 38412905. doi:10.1016/j.radonc.2024.110185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。